The natriuretic peptides. Clinical applications in patients with COPD.
J R
JR
Klinger
M
M
Cutaia
D009320:Atrial Natriuretic Factor / Q000097:blood / Q000235:genetics / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005786:Gene Expression Regulation; D006162:Guanylate Cyclase / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D000860:Hypoxia / Q000188:drug therapy; D008173:Lung Diseases, Obstructive / Q000097:blood / Q000188:drug therapy*; D020097:Natriuretic Peptide, Brain; D020098:Natriuretic Peptide, C-Type; D009419:Nerve Tissue Proteins / Q000097:blood / Q000235:genetics / Q000627:therapeutic use*; D011506:Proteins / Q000627:therapeutic use; D017461:Receptors, Atrial Natriuretic Factor / Q000187:drug effects; D015854:Up-Regulation / Q000235:genetics; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use
D009419:Nerve Tissue Proteins; D011506:Proteins; D014665:Vasodilator Agents; D020097:Natriuretic Peptide, Brain; D020098:Natriuretic Peptide, C-Type; D009320:Atrial Natriuretic Factor; D006162:Guanylate Cyclase; D017461:Receptors, Atrial Natriuretic Factor; C091715:atrial natriuretic factor receptor A; C073616:atrial natriuretic factor receptor C